PharmaEngine (ROCO:4162) Cash Flow for Dividends: NT$0.0 Mil (TTM As of Dec. 2025)


ROCO:4162 PharmaEngine Inc ROCO:4162
79 GF Score
Price NT$62.70
GF Value NT$115.08
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PharmaEngine Cash Flow for Dividends?

PharmaEngine ROCO:4162 +2.79% 79 Cash Flow for Dividends is NT$0.0 Mil as of Dec. 2025. GuruFocus rates ROCO:4162 with a GF Score™ of 79/100 and a GF Value™ of NT$115.08 (Significantly Undervalued). The stock has 3 warning signs investors should review.

PharmaEngine's cash flow for dividends for the three months ended in Dec. 2025 was NT$0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

PharmaEngine's annual payment of dividends declined from Dec. 2023 (NT$-287.2 Mil) to Dec. 2024 (NT$-215.4 Mil) but then increased from Dec. 2024 (NT$-215.4 Mil) to Dec. 2025 (NT$-861.9 Mil).

PharmaEngine Cash Flow for Dividends Related Terms

PharmaEngine Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for PharmaEngine's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaEngine Cash Flow for Dividends Chart

PharmaEngine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -363.99 -387.71 -287.19 -215.44 -861.92

PharmaEngine Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:4162
79GF Score
PharmaEngine Inc ROCO:4162
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaEngine Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of NT$0.0 Mil mean?
PharmaEngine (ROCO:4162) has a Cash Flow for Dividends of NT$0.0 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for PharmaEngine and its competitors.
Is PharmaEngine's Cash Flow for Dividends too high?
PharmaEngine's current Cash Flow for Dividends is NT$0.0 Mil. Overall, PharmaEngine has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's Cash Flow for Dividends compare to VRTX and REGN?
PharmaEngine's Cash Flow for Dividends of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for PharmaEngine and its competitors. PharmaEngine's current Cash Flow for Dividends is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.08, compared to a current price of NT$62.70 — trading 45.5% below its estimated fair value. The current Cash Flow for Dividends is NT$0.0 Mil. PharmaEngine's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current Cash Flow for Dividends is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaEngine (ROCO:4162) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued. The current stock price of NT$62.70 is trading 45.5% below its estimated GF Value™ of NT$115.08. GuruFocus considers PharmaEngine to be Significantly Undervalued.

Key valuation signals for ROCO:4162:

  • Cash Flow for Dividends: NT$0.0 Mil
  • GF Value™: NT$115.08 vs. price of NT$62.70 (45.5% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaEngine Business Description

Address No. 10, Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
79GF Score

Get the complete analysis for ROCO:4162

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$62.70
Price
NT$115.08
GF Value